Novelos Therapeutics acquires Cellectar

Novelos Therapeutics has completed its acquisition of Cellectar and $5.1 million financing to develop three novel cancer-targeted compounds.

Cellectar’s three novel cancer-targeted compounds—COLD, HOT and LIGHT—are selectively taken up and retained in cancer cells (including cancer stem cells), according to Novelos.

COLD, a cancer-targeted chemotherapy, is expected to enter clinical trials late in 2012.

HOT, a small-molecule, broad-spectrum, cancer-targeted radiopharmaceutical that delivers radiation directly and selectively to cancer cells and cancer stem cells, is expected to enter a Phase 1b dose escalation trial in the third quarter of this year and Phase 2 trials in mid-2012 in monotherapy for solid tumors.

LIGHT, a small-molecule cancer imaging compound, is expected to enter Phase 1/2 clinical trials in the middle of this year, according to the Madison, Wis.-based company.

The financing was led by Venture Investors with participation from existing and new investors. Novelos filed a warrant to purchase 192,931 shares of common stock, at an exercise price of $0.75 per share, in connection with the financing.

Around the web

To fully leverage today's radiology IT systems, standardization is a necessity. Steve Rankin, chief strategy officer for Enlitic, explains how artificial intelligence can help.

RBMA President Peter Moffatt discusses declining reimbursement rates, recruiting challenges and the role of artificial intelligence in transforming the industry.

Deepak Bhatt, MD, director of the Mount Sinai Fuster Heart Hospital and principal investigator of the TRANSFORM trial, explains an emerging technique for cardiac screening: combining coronary CT angiography with artificial intelligence for plaque analysis to create an approach similar to mammography.